These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 23462705

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M.
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [Abstract] [Full Text] [Related]

  • 4. Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?
    Mirimanoff RO.
    Chin Clin Oncol; 2015 Dec; 4(4):42. PubMed ID: 26730754
    [Abstract] [Full Text] [Related]

  • 5. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A, Aynsley E, Kumar G, Masinghe S, Anderson M, Veeratterapillay J, Huntley C, Blower A, Green J, Johnson D, Daniel J, Curtis H, Reynolds J, Turnbull M, Harland K, Swingler A, Banham E, Burke K, Bradley J, Greenhalgh A, Peedell C.
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [Abstract] [Full Text] [Related]

  • 6. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S.
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
    Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.
    J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
    [Abstract] [Full Text] [Related]

  • 8. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
    Boily G, Filion É, Rakovich G, Kopek N, Tremblay L, Samson B, Goulet S, Roy I, Comité de l’évolution des pratiques en oncologie.
    J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):348-53. PubMed ID: 22104360
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.
    Cancer; 2017 Aug 15; 123(16):3031-3039. PubMed ID: 28346656
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I, Sandhu S, Lüchtenborg M, Harden S.
    Clin Oncol (R Coll Radiol); 2019 Oct 15; 31(10):681-687. PubMed ID: 31377081
    [Abstract] [Full Text] [Related]

  • 15. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.
    Schanne DH, Nestle U, Allgäuer M, Andratschke N, Appold S, Dieckmann U, Ernst I, Ganswindt U, Grosu AL, Holy R, Molls M, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Guckenberger M.
    Strahlenther Onkol; 2015 Feb 15; 191(2):125-32. PubMed ID: 25159135
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I, Poon I, Yeung L, Erler D, Kim A, Keller B, Lochray F, Jain S, Soliman H, Cheung P.
    Clin Oncol (R Coll Radiol); 2014 Nov 15; 26(11):713-9. PubMed ID: 25085765
    [Abstract] [Full Text] [Related]

  • 18. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
    Mahmood S, Bilal H, Faivre-Finn C, Shah R.
    Interact Cardiovasc Thorac Surg; 2013 Nov 15; 17(5):845-53. PubMed ID: 23900381
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, Han H, de la Zerda A, Bossart E, Huang Z, Schwade JG.
    Clin Lung Cancer; 2007 Sep 15; 8(8):488-92. PubMed ID: 17922973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.